<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1862</number>
    <updateDate>2025-09-23T23:50:27Z</updateDate>
    <updateDateIncludingText>2025-09-23T23:50:27Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2025-05-22</introducedDate>
    <congress>119</congress>
    <legislationUrl>https://www.congress.gov/bill/119th-congress/senate-bill/1862</legislationUrl>
    <committees>
      <item>
        <systemCode>ssfi00</systemCode>
        <name>Finance Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred To</name>
            <date>2025-05-22T15:15:07Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>ORPHAN Cures Act</title>
        <congress>119</congress>
        <number>946</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2025-02-06</actionDate>
          <text>Sponsor introductory remarks on measure. (CR H535-536)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2025-05-22</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance. (text: CR S3119)</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2025-05-22</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>B001261</bioguideId>
        <fullName>Sen. Barrasso, John [R-WY]</fullName>
        <firstName>John</firstName>
        <lastName>Barrasso</lastName>
        <party>R</party>
        <state>WY</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>H001046</bioguideId>
        <fullName>Sen. Heinrich, Martin [D-NM]</fullName>
        <firstName>Martin</firstName>
        <lastName>Heinrich</lastName>
        <party>D</party>
        <state>NM</state>
        <sponsorshipDate>2025-05-22</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects/>
      <policyArea>
        <name>Health</name>
        <updateDate>2025-06-13T13:42:46Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2025-05-22</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2025-07-25T15:38:26Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;strong&gt;Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs.&lt;/p&gt;&lt;p&gt;The Medicare Drug Price Negotiation Program requires the Centers for Medicare &amp;amp; Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition.&lt;/p&gt;&lt;p&gt;The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.&lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>ORPHAN Cures Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>ORPHAN Cures Act</title>
        <updateDate>2025-06-04T03:23:27Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>ORPHAN Cures Act</title>
        <updateDate>2025-06-04T03:23:24Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Optimizing Research Progress Hope And New Cures Act</title>
        <updateDate>2025-06-04T03:23:24Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>A bill to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.</title>
        <updateDate>2025-06-04T03:18:22Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2025-05-22T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-119s1862is/xml/BILLS-119s1862is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2025-05-22</actionDate>
      <text>Read twice and referred to the Committee on Finance. (text: CR S3119)</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
